Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

BACKGROUND: Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population. METHODS: We ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Blasi, Miriam, Eichhorn, Martin E., Christopoulos, Petros, Winter, Hauke, Heußel, Claus Peter, Herth, Felix J., El Shafie, Rami, Kriegsmann, Katharina, Kriegsmann, Mark, Stenzinger, Albrecht, Bischoff, Helge, Thomas, Michael, Kuon, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238242/
https://www.ncbi.nlm.nih.gov/pubmed/35761214
http://dx.doi.org/10.1186/s12890-022-02043-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238242/
https://www.ncbi.nlm.nih.gov/pubmed/35761214
http://dx.doi.org/10.1186/s12890-022-02043-6

Ejemplares similares